Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Intraoperative Tumor Margin Identification With ICG Dye Imaging

NCT: NCT04752137 · RECRUITING

NCT IDNCT04752137
StatusRECRUITING
Start Date2022-05-25
Completion2030-04-01

Brief Summary

In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.

Frequently Asked Questions

What is Intraoperative Tumor Margin Identification With ICG Dye Imaging?

Intraoperative Tumor Margin Identification With ICG Dye Imaging is a clinical trial registered under NCT04752137. Current status: RECRUITING.

What is the status of NCT04752137?

The current status of NCT04752137 (Intraoperative Tumor Margin Identification With ICG Dye Imaging) is: RECRUITING.

When did Intraoperative Tumor Margin Identification With ICG Dye Imaging start?

Intraoperative Tumor Margin Identification With ICG Dye Imaging started on 2022-05-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.